Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatment of AR Positive Metastatic Triple Negative Breast Cancer

NCT03055312 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT03055312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03055312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatment of AR Positive Metastatic Triple Negative Breast Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Terminated
Start date
December 20, 2016
Completion date
November 15, 2020
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple negative breast cancer